NASDAQ$ORIC
ORIC Pharmaceuticals Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported financial results and operational updates.
ORIC Pharmaceuticals reported its Q3 2023 financial results, highlighting progress across its pipeline, including the presentation of initial Phase 1b data for ORIC-114, and steady enrollment across its three clinical trials. The company's cash and investments are expected to fund operations into late 2025.
- Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC, demonstrating a potential best-in-class profile.
- Initial Phase 1b data for ORIC-533 in patients with multiple myeloma to be presented at the 65th ASH Annual Meeting in December 2023.
- Initial Phase 1b data for ORIC-944 in patients with prostate cancer expected in the first quarter of 2024.
- Cash and investments of $256.2 million are expected to fund the operating plan into late 2025.
Headline financials
Revenue & EPS history
ORIC Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
ORIC Pharmaceuticals expects to continue advancing its clinical programs and present initial data for ORIC-533 and ORIC-944 in the coming quarters. The company believes its current cash position is sufficient to fund operations into late 2025.
Tailwinds
- Continued clinical development of ORIC-114.
- Advancement of ORIC-533 into clinical trials.
- Progress in the development of ORIC-944.
- Sufficient cash to fund operations into late 2025.
- Potential advantages of ORIC-114 and ORIC's other product candidates and programs.
Headwinds
- Clinical outcomes of ORIC-114 may materially change as patient enrollment continues or more patient data become available.
- Changes in ORIC’s plans to develop and commercialize its product candidates.
- Potential for clinical trials of ORIC-114, ORIC-533, ORIC-944 or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results.
- Negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials
- Reliance on third parties, including contract manufacturers and contract research organizations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+1.2%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+8.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+14.7%
Q2 2023
Best reaction
-29.8%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +14.7% | +14.9% | +5.7% | |
| Q3 2025 | +0.3% | -5.8% | -23.1% | |
| Q2 2025 | -1.0% | -7.9% | +8.9% | |
| Q1 2025 | +8.7% | +25.8% | +98.9% | |
| Q4 2024 | +0.8% | +2.1% | -43.5% | |
| Q3 2024 | -0.3% | -17.5% | -18.2% | |
| Q1 2024 | -1.0% | -7.4% | -5.6% | |
| Q4 2023 | -4.5% | +0.7% | -33.3% | |
| Q3 2023 | -3.2% | -11.9% | +26.4% | |
| Q2 2023 | +14.7% | +13.8% | +17.3% | |
| Q1 2023 | -0.4% | +0.1% | +11.4% | |
| Q4 2022 | +5.3% | +14.8% | +39.5% | |
| Q3 2022 | +2.8% | +17.9% | +35.4% | |
| Q2 2022 | +3.2% | -2.1% | -26.4% | |
| Q1 2022 | -3.4% | -4.4% | +52.0% | |
| Q4 2021 | -29.8% | -33.0% | -42.6% | |
| Q3 2021 | +7.1% | +8.4% | -7.1% | |
| Q2 2021 | +9.4% | +13.6% | +45.2% | |
| Q1 2021 | +2.1% | +6.1% | -17.0% | |
| Q4 2020 | -6.2% | -7.6% | -10.2% | |
| Q3 2020 | +3.8% | +4.4% | +55.6% | |
| Q2 2020 | +12.5% | +12.4% | +7.8% | |
| Q1 2020 | -8.7% | -11.3% | +7.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro